Share chart Propanc Biopharma, Inc.
Extended chart
Simple chart
About
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. more details| ISIN | US74346N4043 |
|---|---|
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.propanc.com |
| Цена ао | 0.0027 |
| Change price per day: | 0% (0.0002) |
|---|---|
| Change price per week: | 0% (0.0002) |
| Change price per month: | -33.33% (0.0003) |
| Change price per 3 month: | -33.33% (0.0003) |
| Change price per half year: | -83.33% (0.0012) |
| Change price per year: | -98.33% (0.012) |
| Change price per 3 year: | -98.89% (0.018) |
| Change price per 5 year: | -99.94% (0.35) |
| Change price per 10 year: | 0% (0.0002) |
| Change price per year to date: | 0% (0.0002) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. James Nathanielsz | Executive Chairman, CEO, CFO, Treasurer & Secretary | 430.28k | 1974 (51 year) |
| Dr. Julian Norman Kenyon ChB, M.D., MB | Chief Scientific Officer, CTO & Director | 35.99k | 1948 (77 years) |
| Prof. Klaus Kutz | Chief Medical Officer & Member of Scientific Advisory Board | 18.23k |
Address: Australia, Camberwell. VIC, 302. 6 Butler Street - open in Google maps, open in Yandex maps
Website: https://www.propanc.com
Website: https://www.propanc.com
